2023-2024 Mid-Season Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Hospitalizations: U.S. Active Component Service Members

This report provides data supporting use of influenza vaccines among typically healthy service members to prevent influenza hospitalization.

This Surveillance Snapshot provides an overview of the 2023-2024 mid-season analysis of influenza VE against influenza hospitalizations among ACSMs. Data from the DMSS and standardized laboratory data provided by DCPH–Portsmouth were utilized for this analysis.1 A cohort study design was implemented among the population of ACSMs in service at any time between September 1, 2023 and February 14, 2024. 

The outcome was defined as a laboratory-confirmed influenza-positive result (rapid antigen, RT-PCR, or culture influenza assay) with an indication that the individual was hospitalized, or a hospitalization record with the first or second diagnostic International Classification of Diseases, 10th revision code for influenza (J09-J11). Person-time started at the beginning of the surveillance period or entry into active component service (whichever came last) and was censored at either the occurrence of the outcome, end of the surveillance period, or leaving active component or military service (whichever came first). Person-time and outcomes were stratified by vaccination status. Person-time and outcomes occurring prior to vaccination and up to 13 days post-vaccination were defined as unvaccinated. Person-time and outcomes occurring at least 14 days after vaccination were defined as vaccinated. Analyses were conducted for laboratory-confirmed influenza hospitalizations alone and then combined with hospitalization records for influenza. Incidence rates per 100,000 person-years (p-yrs) were calculated and a Poisson regression model was used to calculate adjusted incidence rate ratios (adjusted for sex, age category, prior vaccination [any influenza vaccine within previous five years], and month of diagnosis) and 95% CIs. VE was defined as (1 - OR) x 100. 

There were 47 laboratory-confirmed influenza hospitalizations among ACSMs during the study period. An additional 17 influenza hospitalization records were identified using the encounter data. For both outcomes, the incidence rate of influenza hospitalization among unvaccinated ACSMs was twice the rate of vaccinated ACSMs (lab-confirmed only: 1.0 vs. 0.5 per 100,000 p-yrs; lab-confirmed and hospitalization records: 1.4 vs. 0.7 per 100,000 p-yrs) (Table). Likewise, the adjusted analysis resulted in VE estimates of 46% (95% CI: 2, 70) and 54% (95% CI: 12, 72) for the laboratory-confirmed only and laboratory-confirmed with hospitalization records, respectively. 

Click on the table to access a 508-compliant PDF version

The results of this analysis show moderate protection against hospitalization for influenza among ACSMs from the 2023-2024 seasonal influenza vaccines. Although the number of outcomes are small, the analysis still reached statistical significance and provides data supporting the use of influenza vaccines among typically healthy ACSMs to prevent influenza hospitalizations. 

Reference

  1. Rubertone MV, Brundage JF. The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health. 2002;92(12):1900-1904. doi:10.2105/ajph.92.12.1900

You also may be interested in...

Article
Oct. 1, 2026

Case report: Delayed onset Plasmodium vivax malaria following exposure near the demilitarized zone in the Republic of Korea: A case illustrating the importance of localized exposure history

The Republic of Korea flag flies over the Korean Demilitarized Zone in Panmujom, South Korea.

This case report describes delayed onset P. vivax malaria in a U.S. service member whose non-specific symptom presentation prompted an extensive neurological and infectious disease evaluation before a detailed operational history revealed exposure near the demilitarized zone in the Republic of Korea.

Article
Sept. 1, 2026

Health outcomes of U.S. active component service members working in high risk occupations for blast overpressure exposure: a retrospective cohort study

A U.S. Army Soldier holds his ears as he uses a 120mm Mortar Cannon in a Mortar Carrier Stryker vehicle to fire illumination flares.

This retrospective cohort study examined incidence of initial diagnoses of traumatic brain injury, insomnia, migraine headache, depressive or anxiety disorders, noise-induced hearing injury, and essential hypertension among U.S. active component service members, stratified by those who served in occupations at high risk for blast overpressure exposure ...

Article
July 1, 2026

Surveillance snapshot: Telehealth services among active component members of the U.S. Armed Forces, 2021–2025

Photo by Christina Clarke, U.S. Naval Hospital Naples: The Urology department head at USNH Rota, Spain, waves to staff in USNH Naples, Italy during a virtual cystoscopy between both hospitals. This work must comply with the restrictions shown on https://www.dvidshub.net/about/copyright

This brief annual summary presents trends in telehealth service use among members of the active component of the U.S. Armed Forces, using Defense Medical Surveillance System (DMSS) outpatient and demographic records from January 2021 through December 2025 and identifies the 10 most frequent diagnoses addressed via telehealth.

Refine your search